Henrik Blou, Gubra CEO
April 1, 2025 10:39 AM EDT
R&D

Gubra’s Ab­b­Vie-part­nered amylin looks com­pet­i­tive with Zealand’s in ear­ly tri­al

Elizabeth Cairns

Senior biopharma journalist

GUBamy, the amylin obe­si­ty can­di­date de­vel­oped by Gubra and li­censed to Ab­b­Vie for $350 mil­lion last month, demon­strat­ed en­cour­ag­ing weight loss in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Q&A: John Crow­ley warns biotech is 'dan­ger­ous­ly close' to break­ing, as tar­iff threat, mar­kets bat­ter in­dus­try

Cor­rect­ed: Trump's broad tar­iffs could mark a 'dou­ble wham­my' for phar­ma af­ter FDA cuts

Day af­ter mass FDA fir­ings, new com­mis­sion­er ad­dress­es re­main­ing staff, fo­cus­ing on 'MA­HA' vi­sion

Fir­ings sweep across FDA as for­mer lead­ers lament the gut­ting of drug agency

FDA cuts stir buy­er’s re­morse for some bio­phar­ma lead­ers, once ex­cit­ed by Trump

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times